Advances in Conductive Nanomaterials for Cardiac Arrhythmia and Future Directions in Bioevaluation Strategies

Area of Science:

• Biomaterials Science
• Cardiovascular Research
• Nanotechnology

Background:

• Cardiac arrhythmia (CA) affects nearly 90% of cardiovascular disease patients, often triggered by myocardial infarction (MI).
• Current treatments include pacemakers, cardioversion, ablation, and anti-arrhythmic drugs.
• Emerging strategies utilize conductive nanomaterials (CNMs) in cardiac patches and injectables to restore rhythm post-MI.

Purpose of the Study:

• To review conductive nanomaterials (CNMs) for cardiac arrhythmia treatment.
• To explore the potential of small animal models for evaluating CNM safety and efficacy.
• To address challenges in translating CNM-based therapies to clinical application.

Main Methods:

• Review of existing literature on CNMs (e.g., gold nanoparticles, carbon nanotubes, conjugated polymers) for cardiac applications.
• Analysis of limitations in current in vitro and large animal studies for CNM evaluation.
• Advocacy for the use of small animal models (zebrafish, Drosophila, C. elegans) for preclinical assessment.

Main Results:

• CNMs mimic native cardiac tissue's electrical and mechanical properties, showing promise in vitro.
• Significant gaps exist in assessing CNM safety and efficacy, particularly in large animal models.
• Small animal models offer comprehensive data on pharmacokinetics, pharmacodynamics, genetic effects, and cardiac function.

Conclusions:

• Conductive nanomaterials hold potential for treating cardiac arrhythmia.
• Small animal models provide a viable alternative to overcome hurdles in large animal research for CNM evaluation.
• Utilizing small animal models can accelerate the clinical translation of CNM-based cardiac therapies.